Showing results (71-80 of 451) with videos related to
Sort By:
Pageof 46
Journal of Crohn'S & Colitis|April 4, 2017
Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative ColitisMaja Noman, Marc Ferrante, Raf Bisschops, et al.Ebiomedicine|January 28, 2019
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseBram Verstockt, Sare Verstockt, Jonas Dehairs, et al.Inflammatory Bowel Diseases|July 29, 2009
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante, Geert D'Haens, Olivier Dewit, et al.Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.Gut|October 30, 2010
Management of acute severe ulcerative colitisGert Van Assche, Séverine Vermeire, Paul RutgeertsInflammatory Bowel Diseases|April 3, 2004
Medical therapy for Crohn's disease stricturesGert Van Assche, Karel Geboes, Paul RutgeertsDigestive Diseases (Basel, Switzerland)|May 16, 2006
Emerging biological treatments in inflammatory bowel diseasesGert Van Assche, Séverine Vermeire, Paul RutgeertsBest Practice & Research. Clinical Gastroenterology|March 5, 2009
Serum sickness, encephalitis and other complications of anti-cytokine therapySéverine Vermeire, Gert Van Assche, Paul RutgeertsGastroenterology|March 3, 2009
Biological therapies for inflammatory bowel diseasesPaul Rutgeerts, Severine Vermeire, Gert Van AsscheWorld Journal of Gastroenterology|June 3, 2010
Role of genetics in prediction of disease course and response to therapySeverine Vermeire, Gert Van Assche, Paul RutgeertsPageof 46